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levels compared with patients dialyzed with higher eQB 
(P = 0.002). The all-cause and cardiac mortality rates of 
154 patients, without changes in ED modality for up to 
42 months, were associated with the initial cTnT concen-
trations but not with the initial eQB. In the prospective 
study, higher values for eQB and cTnT were observed dur-
ing HF-HD at weeks 36 (P = 0.045) and 53 (P = 0.01) of 
the present study. The initial cTnT, ∆eQB, and ∆albumin 
influenced the ∆cTnT. The all-cause and cardiac mortal-
ity rates were not different between LF and HF groups at 
21 months after the prospective study was completed.
Conclusion In stable ED patients, higher eQB rates and 
QB/QD values might contribute to silent myocardial injury, 
particularly in patients with lower cTnT levels, but do not 
affect the outcome of ED patients.
Keywords Cardiac troponin T · Dialysate flow · Effective 
blood flow · Extracorporeal dialysis · Mortality
Introduction
Cardiac troponins are specific and sensitive markers of 
ischemic and non-ischemic etiologies of myocardial injury 
[1]. Elevated concentrations of these markers, particularly 
cardiac troponin T (cTnT), have been detected in up to 
94 % of hemodialysis (HD) subjects [2, 3], reflecting multi-
factorial contributions [4–11]. Extracorporeal dialysis (ED) 
might influence serum cardiac troponin concentrations [2, 
3, 5, 8, 12–15].
In the present study, we focused on effective extracor-
poreal blood flow (eQB) rates with respect to serum cTnT 
concentrations. Previous data and prospective studies con-
cerning this subject are scarce. Artunc et al. [4] conducted 
a cross-sectional analysis, showing that the plasma cTnT 
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Purpose We examined the association between extracor-
poreal dialysis (ED)-related effective blood flow (eQB) and 
serum cardiac troponin T (cTnT) as a possible indicator of 
silent myocardial damage in stable ED patients.
Methods In a cross-sectional study, cTnT was determined 
in 247 ED patients dialyzed using stable eQB and dialysate 
flow (QD). In a prospective study, 91 patients were 
switched from low-flux (LF) to high-flux (HF) hemodialy-
sis (HD), and subsequently, the eQB increased, and the QD 
decreased; 65 patients continued LF-HD with stable eQB 
and QD. Clinical/laboratory evaluations were performed at 
0, 15, 36, and 53 weeks from the start of the study.
Results In the cross-sectional study, the main cTnT pre-
dictors were dialysis vintage, age, eQB, phosphorus, and 
C-reactive protein. Patients with cTnT levels in the high-
est quartile were excluded from the analysis, and subjects 
dialyzed with eQB ≤316 ml/min exhibited lower cTnT 
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concentration, but not the cardiac troponin I (cTnI) con-
centration, was positively correlated with the blood pump 
speed in patients based on the use of high-flux (HF) HD. 
During HD sessions with a QB of 250–300 ml/min, the 
observed changes in cTnI were not correlated with the QB 
rate [13], and a QB of 250–350 ml/min did not influence 
the predialytic or the interdialytic cTnT concentration [12].
The aim of the present study was to conduct a cross-sec-
tional study to examine the potential correlation between 
the eQB rate and serum cTnT concentration in patients 
using different ED modalities and assess whether there is 
an association between changes in the eQB rate and serum 
cTnT concentration in a prospective observational study on 
stable patients treated with HF-HD or low-flux (LF) HD. 
The results suggest an association between eQB and cTnT; 
therefore, we also evaluated whether eQB is associated 
with the mortality rate of ED patients.
Subjects and methods
Patients and a study design
In the cross-sectional study, the serum cTnT concentra-
tions were measured in 247 stable ED patients: 54 patients 
used on-line HDF and 35 patients were on HF-HD in dialy-
sis center no 1, while the remaining 158 patients were on 
LF-HD (93 patients were treated in dialysis center no 2, 
and 65 patients were treated in dialysis center no 3). The 
demographic data, clinical parameters, including major car-
diovascular diseases, and laboratory parameters for the ED 
patients are shown in Table 1. The dialysis-related param-
eters for patients treated using different ED modalities dif-
fered between groups (Table 2), but remained stable within 
each group. Among the 247 ED patients, 154 subjects did 
not show changes in ED modality for up to 42 months since 
Table 1  Demographic, clinical, and laboratory data of patients treated using different modalities of extracorporeal dialysis
Results are shown as median and range, mean ± SD, or as numbers with percentage
Statistical tests: C—Chi-square, D—Dunn (post hoc Kruskal–Wallis), MW—Mann–Whitney, K—Kruskal–Wallis
Conversion factors to SI units are as follows: for CRP—9.524, for Ca—0.25, for P—0.323, for ALP—0.0167
ALP total alkaline phosphatase, BMI body mass index, CRP C-reactive protein, cTnT cardiac troponin T, HDF hemodiafiltration, HF-HD high-
flux hemodialysis, LF-HD low-flux hemodialysis, na not available, PTH parathyroid hormone
a Comparison between HDF and LF-HD
b Comparison between HDF and HF-HD
c Comparison between HF-HD and LF-HD
A P value of <0.05 is considered statistically significant
Parameter HDF HF-HD LF-HD P value
n = 54 n = 35 n = 158
Male gender (n, %) 38 (70.4) 18 (51.4) 82 (51.9) 0.03a,C
Age (years) 64.6 ± 12.3 60.6 ± 15.3 64.0 ± 14.4 Ns
Diabetic nephropathy (n, %) 20 (37.0) 6 (17.1) 35 (22.2) 0.03a,C
Coronary artery disease (n, %) 40 (74.1) 11 (31.4) 34 (21.5) <0.0001a,C, <0.0001b,C
 Myocardial infarction (n, %) 27 (50.0) 9 (25.7) 23 (14.6) <0.0001a,C, 0.03b,C
Cardiomyopathies (n, %) 21 (38.9) 6 (17.1) 44 (27.8) 0.035b,C
Valvular disease (n, %) 4 (7.4) 3 (8.7) 34 (21.5) 0.02a,C
Atrial fibrilation (n, %) 3 (5.6) 4 (11.4) 14 (8.7) Ns
Poor control of hypertension (n, %) 7 (13.0) 5 (14.3) 24 (15.8) Ns
Cerebral stroke (n, %) 7 (13.0) 1 (2.9) 10 (6.3) Ns
BMI (kg/m2) 27.1 (18.22–38.16) 23.8 (19.75–47.8) 27.35 (17.75–55.33) 0.01c,D
Albumin (g/l) 37 (26–44) 39 (18–44) 42 (25–49) <0.0001a,c,D
cTnT (ng/ml) 0.050 (0.003–0.315) 0.032 (0.008–0.595) 0.047 (0.004–0.410) 0.09K
CRP (mg/l) 4.0 (0.4–57.7) 6.39 (0.7–89.5) 7.75 (0.7–241.2) 0.3K
β2-Microglobulin (mg/dl) na 2.18 (1.45–2.78) 3.48 (0.09–13.9) 0.07
MW
Ca, mg/dl 8.6 (5.1–11) 8.4 (6.48–9.52) 8.88 (6.6–11.4) 0.004c,D
P (mg/dl) 5.1 (2–10.1) 4.5 (1.6–8) 4.7 (2.4–11.1) 0.07K
PTH (ng/l) 245.3 (9.1–2002.2) 230.8 (21.87–1781.9) 299.8 (4–1962) 0.4K
ALP (IU/l) 74.5 (42–346) 99.0 (40–322) 95.5 (39–725) 0.02a,D
Bicarbonate (mmol/l) 21.7 (13.9–28.8) 22.1 (11.8–30.4) 21.85 (15.1–28.3) 0.7K
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the cross-sectional analysis. The individuals underwent 
an evaluation of all-cause and cardiac mortality rates with 
respect to the initial eQB and cTnT.
LF-HD patients were dialyzed in center no 2 (n = 93) 
and subsequently switched to HF-HD. As a progressive 
increase in eQB to the values recommended for HF dia-
lyzers by their manufacturer was planned in these patients, 
when possible, we designed a prospective study concerning 
the impact of increasing eQB on the serum cTnT concen-
tration. Among 93 patients, 91 subjects provided written 
informed consent to participate in this prospective observa-
tional study. In addition, 65 patients from dialysis center no 
3 were enrolled into a similarly designed prospective obser-
vational study, but with continuation of LF-HD using stable 
eQB and dialysate rates (QD) (see details in the “Results” 
section).
Routine clinical/laboratory evaluations for stable HD 
patients and serum cTnT and β2-microglobulin measure-
ments were performed in both patient groups at 0, 15, 36, 
and 53 weeks from the start of the prospective study. As 
patients presenting cardiac episodes with clinical mani-
festation or other severe instability and individuals who 
underwent renal transplantation during the present study 
(Table 3) were excluded, the serum cTnT concentration 
was analyzed in 44 LF-HD and 58 HF-HD patients. The 
outcome of these patients was evaluated at 21 months after 
the prospective study was completed.
Table 2  Dialysis-related parameters in patients treated using different modalities of extracorporeal dialysis
Results are shown as median and range or as numbers with percentage
Statistical tests: C—Chi-square, D—Dunn (post hoc Kruskal–Wallis)
eQB effective blood flow, HDF hemodiafiltration, HF-HD high-flux hemodialysis, LF-HD low-flux hemodialysis, QD dialysate flow, RRT renal 
replacement therapy
a Comparison between HDF and LF-HD
b Comparison between HDF and HF-HD
c Comparison between HF-HD and LF-HD
A P value of <0.05 is considered statistically significant
Parameter On-line HDF HF-HD LF-HD P value
n = 54 n = 35 n = 158
Total RRT vintage (years) 2.9 (0.05–22.9) 0.2 (0.02–11.1) 2.6 (0.07–25.9) <0.0001b,c,D
Actual RRT vintage (years) 2.4 (0.05–3.8) 0.2 (0.02–11.1) 2.6 (0.07–24.0) <0.0001b,D
0.00002c,D
Arteriovenous fistula (n, %) 50 (92.6) 13 (37.1) 129 (81.6) <0.0001b,c,C
 Arm (n, %) 3 (6.0) 2 (15.4) 41 (31.8) 0.001a,C, 0.01c,C
 Proximal forearm (n, %) 33 (66.0) 4 (30.8) 7 (5.4) <0.0001a,C, < 0.0001b,C
 Distal forearm (n, %) 14 (28.0) 7 (53.8) 81 (62.8) 0.001a,c,C
Permanent catheter (n, %) 4 (7.4) 22 (62.9) 29 (18.4) <0.0001a,b,c,C
Dialysis session duration (min) 240 (240–300) 240 (180–260) 255 (210–320) 0.05b,D, < 0.0001c,D
eQB (ml/min) 354.5 (158–420) 317 (162–392) 304 (148–370) <0.0001a,D, 0.003b,D
QD (ml/min) 503.5 (280–600) 500 (300–500) 500 (300–800) <0.05a,b,D
QB/QD (%) 69.5 (31.4–89.0) 63.8 (32.4–108.0) 60.8 (29.6–107.3) <0.0001a,D, 0.002b,D, 0.03c,D
Kt/Vurea 1.39 (0.92–1.78) 1.25 (0.65–1.99) 1.3 (0.54–1.91) 0.02
a,D
Body weight (kg)
 Before dialysis 78.9 ± 16.5 71.5 ± 15.8 77.5 ± 17.9 Ns
 After dialysis 76.8 ± 16.1 69.9 ± 15.4 75.4 ± 17.5 Ns
 Difference 2.1 ± 1.2 1.6 ± 1.1 2.0 ± 1.0 Ns
Table 3  A patient loss during a 53 weeks prospective study
Results are shown as numbers with percentage
Statistical tests: C—Chi-square, Y—Chi-square with Yates correction
HF-HD high-flux hemodialysis, LF-HD low-flux hemodialysis
a Initial number of patients
Causes of a patient loss HF-HD LF-HD P value
(n = 91)a (n = 65)a
Deaths (n, %) 15 (16.5) 10 (15.4) 1.0C
 Cardiovascular mortality (n, %) 6 (6.6) 7 (10.8) 0.5Y
Non-fatal cardiac episodes (n, %) 11 (12.1) 6 (9.2) 0.8Y
Instability of non-cardiac origin (n, %) 3 (3.3) 4 (6.2) 0.6Y
Renal transplantation (n, %) 4 (4.4) 1 (1.5) 0.6Y
Total 33 (36.3) 21 (32.3) 0.7C
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The dietary and pharmacological treatment of all 
patients was based on a standard of care according to the 
physician. The results of the clinical/laboratory evaluations 
performed during the prospective study were used for the 
appropriate modification of this treatment when necessary.
ED schedule and modalities
In the cross-sectional study, three bicarbonate dialysis ses-
sions per week were prescribed to all patients, except for 
two patients, who underwent four sessions per week. Poly-
sulfone hollow-fiber dialyzers F6HPS–F10HPS (Fresenius 
Medical Care, Bad Hamburg, Germany) or Lo10–Lo23 (B/
Braun Xevonta, Melsungen, Germany) were used for the 
LF-HD patients. Helixone hollow-fiber dialyzers FXCor-
Diax50 or FXCorDiax60 (Fresenius Medical Care, Bad Ham-
burg, Germany) were used for the HF-HD subjects. On-
line HDF was performed using the predilution method and 
FXCorDiax50 or FXCorDiax60 dialyzers.
All patients enrolled into the prospective observational 
study underwent three bicarbonate dialysis sessions per 
week. The LF-HD group continued dialysis treatments 
using Lo10–Lo23 dialyzers, whereas patients who were 
switched from LF-HD to HF-HD changed dialyzers from 
F6HPS–F10HPS to FXCorDiax50 and FXCorDiax60.
Fasting blood samples were drawn prior to the dialysis 
session performed in the middle of the week.
Laboratory measurements
The same analyst from a single laboratory measured the 
serum cTnT using a high-sensitivity method (Troponin T 
hs STAT Elecsys, Roche, Mannheim, Germany). The upper 
reference limit (99th percentile) was 0.014 ng/ml, and the 
95 % CI was 0.0127–0.0249 ng/ml. The blood samples 
were coded for anonymity prior to laboratory determina-
tions. Other parameters were measured using routine labo-
ratory methods.
Statistical analysis
Coded data were the subject of statistical analysis.
The results are shown as the means ± SD or median 
and range, in accordance with the distribution of variables. 
Qualitative parameters are given as percentages. The differ-
ences in continuous variables observed during the prospec-
tive study (∆) were calculated as the difference between 
the results obtained at the analyzed week of the study and 
those detected at the start of the study (∆ values exceeding 
0 indicate an increase during the study, whereas ∆ values 
below 0 indicate a decrease during the study).
Correlations between continuous variables were deter-
mined after calculating the Spearman rank correlation 
coefficient. The multivariate adaptive regression splines 
(MARSplines) model with generalized cross-validation 
(GCV) was used to show indicators of serum cTnT con-
centration. The receiving operating characteristic (ROC) 
curve methodology was applied to determine the predic-
tive values of the eQB rate or QB/QD with respect to the 
serum cTnT concentrations. The results of the continuous 
variables were compared using the Mann–Whitney test, 
Student’s t test, or the Kruskal–Wallis test, with post hoc 
analyses, where applicable. The Q-Cochran test or Chi-
square test (with or without Yates correction) was applied 
to compare dichotomous variables, where appropriate. A 
general linear model (GLM) multiway repeated measures 
analysis was used to compare the results obtained during 
the prospective study.
The Kaplan–Meier method, followed by the log-rank 
test, was used to estimate the significance of the differences 
in cumulative proportion surviving curves characterizing 
the tested groups.
A P value below 0.05 was considered statistically 
significant.
The aforementioned statistical calculations were per-
formed using GraphPad InStat 3.10, 32 bit for Windows, 
created July 9, 2009 (GraphPad Software, Inc., La Jolla, 
CA, USA), CytelStudio version 10.0, created January 16, 
2013 (CytelStudio Software Corporation, Cambridge, 
MA, USA), and Statistica version 10, 2011 (Stat Soft, Inc., 
Tulsa, OK, USA).
Results
Results of the cross‑sectional study
The patients dialyzed using different ED modalities did 
not differ in serum cTnT concentrations (Table 1). The 
eQB rate was significantly higher during HDF than during 
HF-HD or LF-HD (Table 2). The correlations between the 
cTnT values and the eQB rates among the HDF, HF-HD, or 
LF-HD groups were not significant.
In the entire ED group, the cTnT was 0.032, 0.008–
0.595 ng/ml, the eQB rate was 304 ± 54 ml/min, the 
QD rate was 499 ± 54 ml/min, and the QB/QD was 
62 ± 11 %. In the MARSplines model (GCV 0.001, corr. 
R2 = 0.843), the strength of the cTnT indicators in the 
entire ED group was observed in the following order: 
RRT vintage (number of references to this factor 19), 
age (18), eQB rate (17), serum phosphorus (16), serum 
C-reactive protein (CRP) (14), blood bicarbonate (11), 
diabetic nephropathy (10), atrial fibrillation (9), QB/QD 
(3), serum albumin (2), high (arm or proximal forearm) 
placement of the arteriovenous fistula (2), cerebral stroke 
(2), poor control of hypertension (2), cardiomyopathies 
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(1), and coronary artery disease (0). Higher cTnT con-
centrations were primarily associated with longer RRT 
vintage, older age, and higher eQB rate; lower cTnT was 
observed concomitantly with higher serum albumin and 
blood bicarbonate concentrations.
In all ED patients, the correlations between the cTnT 
values and the eQB rate or QB/QD were not significant. 
When patients were divided according to quartiles of cTnT 
concentrations (Q1 and Q4 presented the lowest and the 
highest cTnT values, respectively), a weak positive cor-
relation between cTnT and the eQB rate was observed 
for the combined values of Q1–Q3 quartiles (r = 0.177, 
P = 0.015) (Supplementary Figure 1). An eQB of 316 ml/
min and QB/QD of 66.8 % were indicated in the ROC 
curve methodology as the cutoff values differentiating Q1–
Q3 patients with respect to cTnT concentrations. Subjects 
dialyzed with eQB ≤ 316 ml/min or QB/QD ≤ 66.8 % had 
significantly lower cTnT compared with patients dialyzed 
with QB > 316 ml/min or QB/QD > 66.8 % (Figs. 1, 2, 
respectively). The Q4 patients, with disturbed significance 
of correlation in the entire ED group, had cTnT more 
than fivefold higher (>0.076 ng/ml) than the upper refer-
ence cTnT 99th percentile limit (0.014 ng/ml), represent-
ing seriously ill individuals compared with the remaining 
subjects (Table 4). Categorical variables associated with 
the highest cTnT concentrations included atrial fibrilla-
tion, diabetes mellitus, congestive heart failure, mitral val-
vular disease, cardiomyopathies, coronary artery disease, 
and chronic obstructive pulmonary disease (Table 4, Sup-
plementary Table 1). Among all ED patients, 58 subjects 
did not exhibit any of the aforementioned comorbidities. 
Among this group, a positive correlation between cTnT 
and eQB was revealed (r = 0.271, P = 0.040). There 
were no significant correlations between cTnT and eQB in 
groups showing comorbidities, independent of their num-
ber (Table 5, Supplementary Table 1). Notably, a negative 
correlation was frequently observed between cTnT and 
eQB in patients with comorbidities. In the group includ-
ing patients with five comorbid conditions in each case 
and simultaneously showing the highest median cTnT, 
the Spearman correlation coefficient of −0.285 had an 
absolute value similar to that observed in patients without 
comorbidities, but this value was not significant in a total 
of ten subjects (Table 5).
The outcomes for 154 patients, who did not show 
changes in the ED modality for up to 42 months, were 
dependent on the initial cTnT concentrations (HR 1.97, 
95 % CI 1.39–2.80, P = 0.0002 for all-cause mortality; 
HR 2.18, 95 % CI 1.32–3.60, P = 0.002 for cardiac mortal-
ity), but were not associated with the initial eQB (P = 0.3 
for all-cause mortality; P = 0.4 for cardiac mortality). The 
cumulative proportion surviving curves are presented in 
Supplementary Figures 2–5.
Results of the prospective observational study
The initial demographic, clinical, and laboratory parame-
ters for patients who finished the prospective study without 
symptomatic cardiac events are shown in Supplementary 
Table 2.
The eQB rate during HF-HD increased from 
289 ± 49 to 355 ± 45 ml/min (Fig. 3), whereas the QD 
Fig. 1  Cardiac troponin T in dialysis patients in relation to the effec-
tive blood flow rate. cTnT cardiac troponin T, eQB the effective blood 
flow rate. Number of patients equals 186; patients being in the upper 
cTnT quartile (n = 61) are excluded
Fig. 2  Cardiac troponin T in dialysis patients in relation to the 
effective blood flow-to-dialysate flow ratio. cTnT cardiac troponin 
T, QB/QD the effective blood flow-to-dialysate flow ratio. Num-
ber of patients equals 186; patients being in the upper cTnT quartile 
(n = 61) are excluded
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rate decreased from 497 ± 26 ml/min to 310 ± 45 ml/
min (Supplementary Figure 6); both the eQB rate 
(291 ± 49 ml/min at the start, 293 ± 43 ml/min at the 
end) and the QD rate (500 ml/min) were stable dur-
ing LF-HD. Differences in both parameters were highly 
significant between and within the HF-HD group (GLM 
P < 0.0001). The QB/QD increased during HF-HD from 
59 ± 12 % to 115 ± 17 %, whereas this value remained 
stable during LF-HD (58 ± 10 vs. 58 ± 9 %, Supplemen-
tary Figure 7).
Analysis of the HF‑HD group
We also analyzed the cTnT concentrations during the 
HF-HD course in 58 patients who finished the study 
without symptomatic cardiac events (Fig. 4), and 
Table 4  Comparison of 
demographic, clinical, and 
laboratory parameters of 
extracorporeal dialysis patients 
having serum cardiac troponin 
T concentration in the upper 
quartile with the respective data 
of remaining patients
Results are shown as median and range or as numbers with percentage
Statistical tests: C—Chi-square, MW—Mann–Whitney, Y—Chi-square with Yates correction
Conversion factors to SI units are as follows: for CRP—9.524, for Ca—0.25, for P—0.323, for ALP—
0.0167
ALP total alkaline phosphatase, COPD chronic obstructive pulmonary disease, CRP C-reactive protein, 
cTnT cardiac troponin T, eQB effective extracorporeal blood flow, HDF hemodiafiltration, HF-HD high-
flux hemodialysis, LF-HD low-flux hemodialysis, NYHA New York Heart Association, PTH parathyroid 
hormone
A P value of <0.05 is considered statistically significant
Parameter cTnT quartile 4 cTnT quartiles 1–3 P value
N = 61 N = 186
Male gender (n, %) 40 (65.6) 98 (52.7) 0.08C
Age (years) 67.67 (26.3–86.3) 63.7 (23.1–91.8) 0.02MW
Diabetes mellitus (n, %) 28 (45.9) 44 (23.7) 0.0009C
Diabetic nephropathy (n, %) 25 (41.0) 36 (19.4) 0.0007C
Coronary artery disease (n, %) 28 (45.9) 57 (30.7) 0.03C
 Myocardial infarction (n, %) 20 (32.8) 39 (21.0) 0.06C
Cardiomyopathies (n, %) 26 (42.6) 45 (24.2) 0.006C
Mitral valvular disease (n, %) 15 (24.6) 17 (9.1) 0.004Y
Aortal valvular disease (n, %) 2 (3.3) 7 (3.8) 0.8Y
Atrial fibrillation (n, %) 13 (21.3) 8 (4.3) 0.0001Y
Congestive heart failure 55 (90.2) 111 (59.7) <0.001C
 NYHA (class III–IV) (n, %) 22 (36.1) 21 (11.3) 0.001C
Dialysis modality
 HDF 14 (22.9) 40 (21.5) 0.3C
 HF-HD 5 (8.2) 30 (16.1)
 LF-HD 42 (68.9) 116 (62.4)
eQB (ml/min) 307 (158–410) 312 (148–420) 0.347MW
Poor control of hypertension (n, %) 7 (11.5) 30 (16.2) 0.5Y
Cerebral stroke (n, %) 8 (13.1) 10 (5.4) 0.08Y
COPD (n, %) 8 (13.1) 8 (4.3) 0.03Y
RRT vintage (years) 2.45 (0.11–25.92) 2.43 (0.019–20.65) 0.5MW
Permanent catheter (n, %) 15 (24.6) 40 (21.5) 0.6C
Albumin (g/l) 40 (26–48) 41 (18–49) 0.1MW
cTnT (ng/ml) 0.111 (0.077–0.595) 0.035 (0.003–0.076) <0.0001MW
CRP (mg/l) 8.7 (0.8–241.2) 5.7 (0.4–113.8) 0.04MW
β2-Microglobulin (mg/dl) 3.9 (0.085–7.72) 2.78 (0.085–13.9) 0.01
MW
Ca (mg/dl) 8.9 (6.3–11.4) 8.69 (5.1–11) 0.1MW
P (mg/dl) 4.5 (1.6–11.1) 4.7 (2.1–10.5) 0.7MW
PTH (ng/l) 233 (9.1–1900) 307.5 (4–2002) 0.1MW
ALP (IU/l) 98 (42–446) 91 (39–725) 0.1MW
Bicarbonate (mmol/l) 21.7 (13.9–28.3) 21.9 (11.8–30.4) 0.5MW
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significantly higher cTnT values were observed at 36 
and 53 weeks compared with the start of the study. The 
MARSplines model (GCV 0.0008, corr. R2 = 0.872) 
indicated an increase in the cTnT concentration between 
the start and end of the study (∆cTnT of 0.007, −0.046 
to +0.201 ng/ml), associated with the initial cTnT con-
centration (15 references), an increase in the eQB (7 ref-
erences for ∆eQB of 62, 8–226 ml/min), and a decrease 
in the serum albumin (5 references for ∆albumin of 
−2, −10 to +10 g/dl). The ∆cTnT was negatively cor-
related with the initial cTnT concentration (r = −0.436, 
P = 0.0006, n = 58). Although the entire HF-HD group 
showed a significant increase in the cTnT concentration 
during the prospective study, the cTnT increased in 36 
patients (∆cTnT 0.022, 0.001–0.201 ng/ml), whereas in 
22 patients, either no difference or a decrease in cTnT 
(∆cTnT −0.015, 0.000 to −0.046 ng/ml) was observed. 
Patients showing increased cTnT had lower initial cTnT 
compared with those showing decreased cTnT (0.035, 
0.009–0.268 vs. 0.063, 0.026–0.141, P = 0.002). The 
initial and increased eQB values were similar in both 
groups (P = 0.250 and P = 0.374, respectively) during 
the study.
Table 5  Correlation of serum 
cTnT concentration and eQB 
in cross-sectional patients 
categorized by number of 
comorbidities (n = 247)
Results are shown as median and range
cTnT cardiac troponin T, eQB effective extracorporeal blood flow
a Comorbidities: atrial fibrillation, cardiomyopathies, chronic obstructive pulmonary disease, congestive 
heart failure, coronary artery disease, diabetes mellitus, mitral valvular disease





cTnT (ng/ml) eQB (ml/min) Spearman rank  
correlation
r P
0 58 0.025, 0.003–0.170 312, 160–407 0.271 0.040
1 54 0.043, 0.009–0.410 305.5, 156–395 −0.172 0.214
2 56 0.056, 0.010–0.207 301, 160–400 0.060 0.659
3 50 0.052, 0.009–0.595 311.5, 159–398 −0.098 0.497
4 19 0.075, 0.010–0.201 322, 148–420 −0.017 0.946
5 10 0.110, 0.030–0.315 309.5, 189–393 −0.285 0.427
4/5 19/10 0.082, 0.010–0.315 320, 148–420 −0.111 0.565
Fig. 3  Effective blood flow during a prospective study in patients 
using high-flux hemodialysis or low-flux hemodialysis. HF-HD high-
flux hemodialysis, LF-HD low-flux hemodialysis, eQB the effective 
blood flow rate
Fig. 4  Serum cardiac troponin T concentrations during a prospective 
study in patients using high-flux hemodialysis or low-flux hemodialy-
sis. cTnT cardiac troponin T, HF-HD high-flux hemodialysis, LF-HD 
low-flux hemodialysis. Significant differences in the post hoc GLM 
analysis: HF-HD versus LF-HD: 36th week: P = 0.045, 53rd week: 
P = 0.01. HF-HD course: 0 versus 36th week: P = 0.004, 0 versus 
53rd week: P = 0.01; LF-HD course: 0 versus 15th week: P = 0.02, 
15th versus 53rd week: P = 0.01
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Other changes in clinical/laboratory parameters were 
not significant or indicated improvement compared with 
the beginning of the study. The latter was observed in the 
case of the decreased administration of anti-hypertensive 
medication (Supplementary Figure 8), an increase in eKt/V 
(1.29, 0.54–1.69 vs. 1.38, 0.70–1.64, P < 0.05) and HDL-
cholesterol (40, 21–90 vs. 44.5, 24–86 mg/dl, P = 0.011), 
and a decrease in β2-microglobulin (3.8, 0.99–13.9 vs. 2.6, 
0.73–5.25 mg/dl, P < 0.05).
Analysis of the LF‑HD group
During LF-HD course, an increase in cTnT in the 44 
patients who finished the study without symptomatic car-
diac events was observed between the start and the 15th 
week of the study (Fig. 4). The MARSplines model (GCV 
0.00006, corr. R2 = 0.999) showed that this increase in 
cTnT concentration was influenced by an increase in serum 
phosphorus (21 references for ∆phosphorus of 0.44, −1.80 
to +3.52 mg/dl), older age (10 references), and diabetic 
nephropathy (9 references). The serum phosphorus lev-
els observed after 15 weeks were higher in 31 (70.5 %) 
of the 44 LF-HD patients compared with the initial phos-
phorus values. Thus, an intense decrease in serum phos-
phorus through dietary changes and the administration of 
pharmacological medication became the therapeutic goal 
in all LF-HD subjects showing serum phosphorus levels 
higher than the reference limit. In response, the cTnT con-
centration increased, while the phosphorus concentration 
decreased, and at the end of the study, the levels of these 
parameters were not different from those observed at the 
beginning of the study (Fig. 4, Supplementary Figure 9).
LF-HD patients with stable eQB during the 53 weeks 
of the study were divided into two subgroups according 
to the initial eQB. These subgroups were analyzed sepa-
rately and compared to determine whether differences in 
the initial eQB affected the final concentrations of plasma 
cTnT. Among this group, 22 patients were dialyzed with 
eQB < 300 ml/min, and the median initial cTnT was 0.039 
(0.011–0.127) ng/ml, while the remaining 22 subjects were 
dialyzed with eQB ≥ 300 ml/min, and the initial cTnT was 
0.045 (0.004–0.160) ng/ml. After 53 weeks of prospec-
tive observation with unchanged eQB, the cTnT levels 
were similar (0.039, 0.015–0.134 ng/ml and 0.045, 0.006–
0.122 ng/ml, respectively).
During the 53 weeks of the prospective study, the serum 
albumin level (41.5 ± 3.5 vs. 34.3 ± 3.9 g/dl, P < 0.0001) 
and HDL-cholesterol (40, 23–73 vs. 37, 21–71 g/dl, 
P < 0.05) were decreased, whereas the β2-microglobulin 
(2.35, 0.09–6.28 vs. 3.51, 0.50–9.97 mg/dl, P < 0.05), para-
thyroid hormone (PTH, 481, 4–1900 vs. 600, 5–1900 pg/
ml, P < 0.05), and total alkaline phosphatase (ALP, 95, 
47–354 vs. 123, 78–687 U/l, P < 0.05) were increased in 
LF-HD patients.
Comparison of the HF‑HD and LF‑HD groups
Patients of both prospective groups initially showed simi-
lar cTnT at the beginning of the study (Fig. 4). During the 
study, significant differences in serum cTnT concentra-
tions were revealed between both HD modalities (GLM 
P = 0.019): Compared with the LF-HD group, higher 
cTnT levels were observed in the HF-HD group at 36 and 
53 weeks. Additionally, both groups differed in serum CRP, 
with a decrease observed during HF-HD and an increase 
observed during LF-HD (GLM P < 0.008). A similar pat-
tern of changes was observed for β2-microglobulin (GLM 
P < 0.0001). The time-dependent increments for ALP 
(GLM P = 0.0005) and PTH (GLM P < 0.0001) were 
more pronounced in LF-HD than in HF-HD patients. GLM 
analysis indicated higher serum phosphorus during LF-HD 
than during HF-HD (GLM P < 0.0006), but this difference 
was ameliorated by dietary and pharmacological treatments 
in the LF-HD patients. A decrease in serum albumin was 
observed in both groups, but this decrease was more evi-
dent in LF-HD patients (GLM P < 0.0001). The control of 
hypertension improved during HF-HD, but remained worse 
in LF-HD patients (Supplementary Figure 8).
During the prospective study, there were no signifi-
cant differences between the all-cause and cardiac mor-
talities and frequency of non-fatal cardiac episodes in 
both groups (Table 3). At 21 months after the study was 
completed, LF-HD and HF-HD patients did not dif-
fer in all-cause and cardiac mortality rates (Supplemen-
tary Figures 10 and 11), although these patients signifi-
cantly differed in eQB (293 ± 43 vs. 355 ± 45 ml/min, 
respectively, P < 0.000001) and cTnT (0.046 ± 0.031 vs. 
0.074 ± 0.061 ng/ml, respectively, P = 0.01) at the begin-
ning of the 21-month observation period.
Discussion
No correlation between the QB rate and cardiac troponin 
levels was observed in previous studies [12, 13], although 
one study showed a positive weak correlation [4]. There 
was also no such correlation observed in the present study 
after analyzing all ED patients included in the cross-sec-
tional study.
The lack of a direct correlation between eQB and cTnT 
might reflect multiple factors influencing cardiac troponins 
[4, 6, 8, 9, 11], which obviously differentiate ED patients, 
independent from the eQB rate. Nevertheless, a predictive 
value for the eQB rate with respect to the serum cTnT was 
detected in the present study for the ED group among other 
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well-known cTnT determinants, including dialysis vintage 
[4, 5], age [8], diabetes [6], serum phosphate [9], or serum 
CRP [4–6]. A significant correlation between eQB and 
cTnT was observed at lower cTnT concentrations, particu-
larly in patients without any comorbidities (median cTnT 
of 0.025 ng/ml) or patients with less advanced comorbid 
conditions and cTnT levels in the Q1–Q3 quartiles (median 
cTnT of 0.035 ng/ml). In patients with high cTnT resulting 
from multiple contributing factors, the serum cTnT did not 
correlate with the eQB; indeed, this correlation was rather 
negative, suggesting a lower cTnT at the higher QB rates. It 
is reasonable to speculate that the response to the eQB rate 
might be different in ED patients without comorbid condi-
tions, in whom higher eQB rates contribute to myocardial 
injury and increased serum cTnT, and in ED patients suf-
fering from multiple comorbidities, primarily of cardiac 
origin, higher eQB might decrease cTnT.
In the course of ED therapy, serum cTnT levels might 
increase, reflecting influences of uremia and dialysis-asso-
ciated factors on myocardium [2, 3, 5, 8, 12–15]. Based 
on patients treated with LF-HD without any changes in 
eQB and QD, these factors were considered as indicators 
of time-dependent differences in serum cTnT levels. At 
the start of the prospective study, compared with HF-HD 
patients, LF-HD subjects were younger and had better con-
trol of hypertension, no cerebral strokes in the past, lower 
β2-microglobulin levels, and higher PTH concentrations. 
However, despite these differences, initial serum cTnT con-
centrations were comparable in both groups.
The prospective study revealed that the gradual increase 
in eQB at an average rate of 66 ml/min did not result in 
significant differences in the frequencies of both cardio-
vascular mortality and non-fatal cardiac episodes com-
pared with the respective frequencies for patients dialyzed 
with stable eQB. To determine the impact of increasing 
eQB rates on serum cTnT concentrations as an indicator 
of silent myocardial injury, patients showing symptomatic 
cardiac episodes and instability of non-cardiac origin were 
not included in the analyses, and the results revealed that 
the serum cTnT concentration might increase during HD 
treatment, even in stable patients, free from symptomatic 
cardiac events and without other remarkable changes in 
health status. Increases in serum cTnT were associated with 
higher cTnT concentrations in the present cross-sectional 
study (age, eQB, serum phosphorus, serum CRP, diabetic 
nephropathy, and serum albumin), consistent with previ-
ous studies [4–7, 9]. The factors likely contributing to 
the increase in cTnT were, however, different in both HD 
groups showing similar initial cTnT concentrations. These 
factors did not include those reported as different between 
the groups at the study beginning. Therefore, the initial dif-
ferentiating factors did not affect changes in cTnT and were 
not indicated in the well-fitted MARSplines model.
In LF-HD patients, an increase in cTnT was revealed 
after 15 weeks, and this effect was transient, as the primary 
contributor, serum phosphorus, was efficiently decreased 
in the following weeks. In HF-HD patients, elevations in 
cTnT were evidently associated with increased eQB and 
QB/QD. Because eQB and QD did not return to the initial 
values, we cannot determine whether this increase in cTnT 
was reversible.
In stable HD patients, the serum cTnT increased with 
gradually increasing eQB. In HD patients using hollow 
cuprophan fiber dialyzers, an increase in the QB rate from 
200 to 400 ml/min with a stable QD rate of 500 ml/min 
was associated with increased amounts of C3a, the termi-
nal complement complex involving the sequential assem-
bly of the precursor proteins C5b and C6–C9 [16]. Addi-
tional biocompatible dialysis membranes generated lower 
but detectable increments in C3a [17, 18]. In experimental 
studies evaluating the role of C5 and C3a in myocardial 
ischemia, Busche et al. [19] showed that C3a and C5 were 
involved in increments of serum cTnI concentrations fol-
lowing myocardial ischemia/reperfusion injury. Therefore, 
myocardial ischemia/reperfusion injury might represent a 
potential mechanism of myocardial injury in patients with 
higher QB rates.
However, the results of the present study also revealed 
that increased cTnT was negatively correlated with the ini-
tial cTnT concentration when an increase in the eQB was 
observed during HF-HD. Patients with high cTnT concen-
trations resulting from multiple contributing factors might 
show no or lower increments or even a decrease in cTnT 
levels when eQB is high during HF-HD. This observation 
is consistent with the results of the present cross-sectional 
study.
However, the factors causing the increase or decrease in 
cTnT in patients with higher initial cTnT levels during the 
prospective study remain unknown, and whether a decrease 
in serum cTnT concentration reflects a decrease in myocar-
dial injury or only a removal of cTnT from the blood as a 
result of the use of more efficient HD compared with previ-
ously applied therapies remains to be determined.
HF-HD diminishes uremic toxicity more effectively than 
LF-HD [20–22], suggesting a beneficial effect on myo-
cardium, although HF-HD is associated with higher eQB 
rates. The benefits of HF-HD compared with LF-HD were 
revealed in the present study with respect to serum albumin, 
CRP, β2-microglobulin, PTH, ALP, and phosphorus. Ure-
mic patients showing worsened conditions (diabetic sub-
jects) or biochemistries (serum albumin ≤ 4 g/dl) showed 
improved survival on HF-HD compared with LF-HD [20]. 
The benefits of HF-HD might at least partially counterbal-
ance the negative effects of increases in both eQB and QB/
QD and elevations in serum cTnT. According to Palmer 
et al. [23], cardiovascular mortality was reduced by 17 % in 
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patients receiving HF-HD. However, these authors did not 
analyze eQB.
However, when high-efficiency dialysis techniques 
requiring higher eQB rates are applied to patients with 
high cTnT concentrations reflecting comorbid diseases, the 
serum cTnT, similar to other proteins, might decrease dur-
ing transmembrane leakage from the blood to the dialysate. 
This phenomenon is particularly relevant for proteins 
with lower molecular weights [24, 25]. In patients receiv-
ing HF-HD in the prospective study, a significant protein 
decrease was observed for β2-microglobulin. However, in 
a recent study, Laveborn et al. [26] indicated that HF-HD 
or HDF might mask increases in the cTnT concentration, 
reflecting the removal of cTnT and associated fragments 
during ED using more efficient dialysis techniques. A 
decrease in natural cTnT concentrations disrupts the rela-
tionship between cTnT and tested factors, such as eQB or 
survival. Thus, it is likely that the evaluation of echocar-
diographic parameters closely associated with serum cTnT 
(E/E`, right ventricular Tei index, left ventricular ejection 
fraction [27]) might be helpful in determining whether a 
decrease in cTnT levels indicates the amelioration of car-
diac damage during the transmembrane loss of cTnT.
Serum cTnT is an independent predictor of all-cause 
and cardiovascular mortalities in HD patients [28], as con-
firmed in the present study. The eQB rate was not associ-
ated with all-cause or cardiac mortality in ED patients, the 
cross-sectional group or the prospective groups.
A lack of association between eQB and survival might 
reflect the following conditions:
•	 A direct relationship between eQB and cTnT only at 
lower serum cTnT concentrations,
•	 An unclear influence of eQB on serum cTnT in asymp-
tomatic patients with high cTnT concentrations,
•	 The removal of cTnT to the dialysate during HF-HD or 
HDF,
•	 The amelioration of the potential negative cardiac 
effects of higher eQB rates, and
•	 The analysis of survival rates based on the initial eQB 
rates, considering that the eQB might differ in consecu-
tive months or years.
Lipschultz et al. [29] suggested that increased serum 
cTnT concentrations “are not artifactual, but are genuine 
indicators of cardiomyocyte damage.” Therefore, elevations 
in cTnT without cardiac symptoms should be seriously con-
sidered and prevented. The results of the present study indi-
cated that a decrease in the elevated serum phosphorus con-
centration, associated with increased cTnT, might restore 
cTnT concentrations to the initial levels. When patients are 
maintained under relatively stable conditions during HD, 
the serum cTnT levels might also remain unchanged at 
least up to 53 weeks, irrespective of the eQB rates, consist-
ent with the prospective observations in LF-HD patients.
In summary, in patients receiving stable ED, silent ongo-
ing myocyte injury, indicated as increased serum cTnT 
concentrations, is primarily associated with comorbidities, 
longer RRT vintage, older age, and high serum phosphorus 
and CRP concentrations. Higher eQB rates increase cTnT 
levels, thereby resulting in myocardial damage during ED 
in subjects with lower cTnT concentrations, which does not 
affect the outcome of ED patients. The impact of higher 
eQB rates on further myocardial injury in patients showing 
high cTnT levels remains unclear and requires additional 
studies.
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